"Mayne Pharma contraceptive product set to hit the US" By Emma Koehn Sydney Morning Herald "ASX- listed pharmaceuticals maker Mayne is kicking off the week with new product announcements, with its long-awaited contraceptive Nextstellis hitting the US market this week. Mayne has a 20-year exclusive licence for the product, which was developed by Belgian biotech Mithra. Nexstellis is the first new contraceptive pill containing estrogen to be approved by the US regulator in 50 years. Mayne Pharma CEO Scott Richards sees the approval of Nextstellis as a significant milestone. “Our key priorities with this launch are to educate the market on the benefits of Nextstellis and the new estrogen E4, gain broad payor acceptance and reimbursement, and ultimately become the preferred branded oral contraceptive in the market,” said chief executive Scott Richards.The $625 million company has also bagged the Australian licencing rights to two medications to treat solar keratosis, a skin condition caused by sustained sun exposure."
MYX Price at posting:
34.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)